Published in Liver Int on May 21, 2010
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol (2014) 0.90
Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. Int J Clin Exp Med (2015) 0.78
Influence of age and HBeAg status on the correlation between HBV DNA and hepatic inflammation and fibrosis in chronic hepatitis B patients. Dig Dis Sci (2012) 0.77
Different Mechanisms May Exist for HBsAg Synthesis and Secretion During Various Phases of Chronic Hepatitis B Virus Infection. Med Sci Monit (2017) 0.75
Current role of transient elastography in the management of chronic hepatitis B patients. Ultrasonography (2016) 0.75
HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication. BMC Gastroenterol (2014) 0.75
Natural history of chronic hepatitis B: extending the REVEAL study. Liver Int (2010) 0.75
Methodological considerations in studying natural history of HBeAg-negative and -positive chronic hepatitis B. Liver Int (2011) 0.75
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology (2011) 3.13
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 2.80
Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol (2010) 2.61
New insight in the pathobiology of hepatitis B virus infection. Gut (2012) 2.54
The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol (2013) 2.41
Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology (2005) 2.25
Hepatitis C virus resistance to protease inhibitors. J Hepatol (2011) 2.18
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology (2002) 2.01
SINGLE-01: a randomized, controlled trial comparing the efficacy and depth of insertion of single- and double-balloon enteroscopy by using a novel method to determine insertion depth. Gastrointest Endosc (2012) 1.91
Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res (2003) 1.88
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81
Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis (2005) 1.81
Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology (2002) 1.79
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
HBV drug resistance: mechanisms, detection and interpretation. J Hepatol (2006) 1.71
Lamivudine resistant occult HBV: implications for public health? J Hepatol (2003) 1.64
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol (2007) 1.54
Initial experience with capsule endoscopy at a major referral hospital. Med J Aust (2003) 1.54
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS (2006) 1.52
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Prospective study of the clinical impact of EUS. Gastrointest Endosc (2005) 1.49
Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. Gut (2012) 1.47
Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol (2002) 1.45
Accuracy of computed tomography guided core needle biopsy of musculoskeletal tumours. ANZ J Surg (2005) 1.42
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Noninvasive imaging of the small bowel in Crohn's disease: the final frontier. Inflamm Bowel Dis (2011) 1.40
Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology (2007) 1.38
Management of treatment failure in chronic hepatitis B. J Hepatol (2012) 1.33
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol (2007) 1.28
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis (2011) 1.24
Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology (2002) 1.22
The effect of erythromycin on video capsule endoscopy intestinal-transit time. Gastrointest Endosc (2006) 1.22
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology (2003) 1.22
Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis (2012) 1.19
Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS (2003) 1.15
Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care (2005) 1.14
The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol (2011) 1.13
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother (2007) 1.13
Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res (2006) 1.11
Optimising the management of soft tissue tumours. Pathology (2011) 1.10
Prospective assessment of magnetic resonance cholangiopancreatography for noninvasive imaging of the biliary tree. Gastrointest Endosc (2002) 1.09
Confocal endomicroscopy for in vivo detection of microvascular architecture in normal and malignant lesions of upper gastrointestinal tract. J Gastroenterol Hepatol (2007) 1.08
Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol (2003) 1.08
UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos (2002) 1.08
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology (2009) 1.07
Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol (2003) 1.05
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother (2002) 1.05
Percutaneous radiofrequency ablation for osteoid osteoma: experience with a new treatment. Med J Aust (2006) 1.04
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int (2013) 1.04
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology (2009) 1.03
The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Med J Aust (2007) 1.01
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Preprotachykinin-A gene deletion protects mice against acute pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol (2003) 1.00
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. J Gastroenterol Hepatol (2012) 0.99
Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther (2009) 0.98
Increased prevalence of HBV envelope mutants in Taiwan: an emerging public health risk or a false alarm? Gastroenterology (2012) 0.98
18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skeletal Radiol (2011) 0.98
HBV genotyping and analysis for unique mutations. Methods Mol Med (2004) 0.97
An update on HDV: virology, pathogenesis and treatment. Antivir Ther (2013) 0.97
Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther (2012) 0.97
Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol (2010) 0.97
Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis. Pancreas (2002) 0.96
Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.96
Visceral hypersensitivity following cold water intake in subjects with irritable bowel syndrome. J Gastroenterol (2006) 0.95
Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol (2008) 0.95
Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ (2009) 0.95
The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int (2009) 0.95
Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol (2010) 0.95
New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology (2003) 0.94
Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr (2007) 0.93
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis (2013) 0.93
Plasma and gastric mucosal 5-hydroxytryptamine concentrations following cold water intake in patients with diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol (2007) 0.93
MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation. Am J Physiol Gastrointest Liver Physiol (2002) 0.92
Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol (2011) 0.92
Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev (2007) 0.92
Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J Gastroenterol Hepatol (2009) 0.92
Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR. Methods Mol Med (2004) 0.90
Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology (2012) 0.89
Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS (2011) 0.88
Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol (2004) 0.88